Provid Pharmaceuticals, Inc., a smll molecule drug discovery company, provides early stage research and translational drug development services to biotech and pharmaceutical industries - optimizing drug candidates for biological targets.. Soon after its founding , the firm licensed exclusive worldwide rights from the University of Pennsylvania to intellectual property relating to small-molecule peptide mimetics. Provid offers client drug discovery and development services, including analysis and solution design, expert medicinal chemistry, project management and drug development, and intellectual and experimental due diligence, as well as preclinical development, IND-enabling studies, and regulatory and clinical development support services. Its drug discovery pipeline includes targets for a range of diseases, such as multiple sclerosis, rheumatoid arthritis, celiac disease, cancer, type 1 diabetes, atherosclerosis, infectious diseases, and other autoimmune diseases. Having talent and expertise in synthetic and medicinal chemistry, along with peptide and peptide mimetics technology and in structure-based drug design. Their experience makes Provid the premier drug discovery company for early stage research and translational drug development.
